Latest Breaking News On - Philippe archinard - Page 3 : comparemela.com
Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022
myvac
TG4001
: expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data
BT-001
Invir.IO platform following the partial sale of the stake in Tasly BioPharmaceuticals in 2020
Conference call in English scheduled today at 6:00 p.m. CET Video conference in French on March 10 at 10:00 a.m. CET (details at the end of the release)
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2020 and provides an update on its product pipeline.
Germany
United-states
United-kingdom
Spain
France
Belgium
French
Spanish
Lucie-larguier
Transgene-euronext
Philippe-archinard
Ben-brahim
(1)
LUND, Sweden and STRASBOURG, France, Dec. 21, 2020 /PRNewswire/ BioInvent International AB ( BioInvent ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vaccinia virus BT-001.
BT-001 is a best-in-class oncolytic
Vaccinia virus. It has been generated using Transgene s Invir.IO platform and its patented large-capacity VVcopTK-RR-
Sweden
United-states
France
Belgium
French
Lucie-larguier
Philippe-archinard
Martin-welschof
Mary-ann-chang
Sylvie-berrebi
Citigate-dewe-rogerson
Astrazeneca